NO20072302L - Modulatorer av hepatocyttvekstfaktoraktivator - Google Patents
Modulatorer av hepatocyttvekstfaktoraktivatorInfo
- Publication number
- NO20072302L NO20072302L NO20072302A NO20072302A NO20072302L NO 20072302 L NO20072302 L NO 20072302L NO 20072302 A NO20072302 A NO 20072302A NO 20072302 A NO20072302 A NO 20072302A NO 20072302 L NO20072302 L NO 20072302L
- Authority
- NO
- Norway
- Prior art keywords
- growth factor
- modulators
- hepatocyte growth
- factor activator
- activator
- Prior art date
Links
- 108010043026 HGF activator Proteins 0.000 title abstract 2
- 102100031465 Hepatocyte growth factor activator Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61565704P | 2004-10-04 | 2004-10-04 | |
| PCT/US2005/036300 WO2006042173A2 (en) | 2004-10-04 | 2005-10-03 | Modulators of hepatocyte growth factor activator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072302L true NO20072302L (no) | 2007-06-28 |
Family
ID=36148972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072302A NO20072302L (no) | 2004-10-04 | 2007-05-03 | Modulatorer av hepatocyttvekstfaktoraktivator |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20060147451A1 (OSRAM) |
| EP (1) | EP1809673B1 (OSRAM) |
| JP (2) | JP4937127B2 (OSRAM) |
| KR (1) | KR101252306B1 (OSRAM) |
| CN (1) | CN101035810B (OSRAM) |
| AU (1) | AU2005294146B2 (OSRAM) |
| BR (1) | BRPI0515670A (OSRAM) |
| CA (1) | CA2577598C (OSRAM) |
| ES (1) | ES2398528T3 (OSRAM) |
| IL (1) | IL181450A0 (OSRAM) |
| NO (1) | NO20072302L (OSRAM) |
| NZ (1) | NZ553327A (OSRAM) |
| RU (1) | RU2418004C2 (OSRAM) |
| WO (1) | WO2006042173A2 (OSRAM) |
| ZA (1) | ZA200701789B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060147451A1 (en) | 2004-10-04 | 2006-07-06 | Genentech, Inc. | Modulators of hepatocyte growth factor activator |
| US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
| DK2056874T3 (da) * | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
| CN101652389A (zh) * | 2007-02-09 | 2010-02-17 | 健泰科生物技术公司 | 抗robo4抗体及其用途 |
| EP3130607B1 (en) | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| BR112012009245A2 (pt) * | 2009-10-19 | 2019-09-24 | Genentech Inc | ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo'' |
| US20110206704A1 (en) * | 2009-10-19 | 2011-08-25 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activator |
| EP2491059B1 (en) | 2009-10-22 | 2015-02-25 | F.Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods using same |
| TW201300417A (zh) | 2010-11-10 | 2013-01-01 | Genentech Inc | 用於神經疾病免疫療法之方法及組合物 |
| WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
| JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法 |
| WO2016130726A1 (en) | 2015-02-10 | 2016-08-18 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| WO2023172863A1 (en) * | 2022-03-07 | 2023-09-14 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-cd36 antibodies and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| CA2102463A1 (en) * | 1992-11-05 | 1994-05-06 | Mitsubishi Chemical Corporation | Protein and gene encoding said protein |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US7045602B2 (en) * | 2000-12-05 | 2006-05-16 | Mitsubishi Chemical Corporation | Specific antibody directed to active hepatocyte growth factor activator and method for using the same |
| JP4090236B2 (ja) * | 2000-12-05 | 2008-05-28 | 三菱化学株式会社 | 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法 |
| US20060147451A1 (en) | 2004-10-04 | 2006-07-06 | Genentech, Inc. | Modulators of hepatocyte growth factor activator |
-
2005
- 2005-10-03 US US11/242,617 patent/US20060147451A1/en not_active Abandoned
- 2005-10-03 BR BRPI0515670-0A patent/BRPI0515670A/pt not_active IP Right Cessation
- 2005-10-03 CN CN2005800338036A patent/CN101035810B/zh not_active Expired - Fee Related
- 2005-10-03 NZ NZ553327A patent/NZ553327A/en not_active IP Right Cessation
- 2005-10-03 CA CA2577598A patent/CA2577598C/en not_active Expired - Fee Related
- 2005-10-03 JP JP2007535866A patent/JP4937127B2/ja not_active Expired - Fee Related
- 2005-10-03 AU AU2005294146A patent/AU2005294146B2/en not_active Ceased
- 2005-10-03 ES ES05810858T patent/ES2398528T3/es not_active Expired - Lifetime
- 2005-10-03 WO PCT/US2005/036300 patent/WO2006042173A2/en not_active Ceased
- 2005-10-03 EP EP05810858A patent/EP1809673B1/en not_active Expired - Lifetime
- 2005-10-03 ZA ZA200701789A patent/ZA200701789B/xx unknown
- 2005-10-03 KR KR1020077007643A patent/KR101252306B1/ko not_active Expired - Fee Related
- 2005-10-03 RU RU2007116806/10A patent/RU2418004C2/ru not_active IP Right Cessation
-
2007
- 2007-02-20 IL IL181450A patent/IL181450A0/en unknown
- 2007-05-03 NO NO20072302A patent/NO20072302L/no not_active Application Discontinuation
-
2008
- 2008-08-01 US US12/184,969 patent/US7825221B2/en not_active Expired - Fee Related
-
2010
- 2010-09-15 US US12/883,033 patent/US8399629B2/en not_active Expired - Fee Related
-
2011
- 2011-08-15 JP JP2011177452A patent/JP5554298B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-12 US US13/765,625 patent/US8969528B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1809673A2 (en) | 2007-07-25 |
| KR101252306B1 (ko) | 2013-04-08 |
| EP1809673B1 (en) | 2012-11-28 |
| IL181450A0 (en) | 2007-07-04 |
| US20090047291A1 (en) | 2009-02-19 |
| JP2012025752A (ja) | 2012-02-09 |
| KR20070102470A (ko) | 2007-10-18 |
| US20110098449A1 (en) | 2011-04-28 |
| US7825221B2 (en) | 2010-11-02 |
| US20130217862A1 (en) | 2013-08-22 |
| CA2577598C (en) | 2016-09-20 |
| JP4937127B2 (ja) | 2012-05-23 |
| CN101035810A (zh) | 2007-09-12 |
| CA2577598A1 (en) | 2006-04-20 |
| NZ553327A (en) | 2010-02-26 |
| HK1105006A1 (en) | 2008-02-01 |
| CN101035810B (zh) | 2011-04-06 |
| JP2008515918A (ja) | 2008-05-15 |
| US8969528B2 (en) | 2015-03-03 |
| AU2005294146A1 (en) | 2006-04-20 |
| RU2007116806A (ru) | 2008-11-10 |
| ES2398528T3 (es) | 2013-03-19 |
| JP5554298B2 (ja) | 2014-07-23 |
| AU2005294146B2 (en) | 2011-09-15 |
| BRPI0515670A (pt) | 2008-07-29 |
| WO2006042173A3 (en) | 2006-08-17 |
| WO2006042173A2 (en) | 2006-04-20 |
| US8399629B2 (en) | 2013-03-19 |
| US20060147451A1 (en) | 2006-07-06 |
| RU2418004C2 (ru) | 2011-05-10 |
| ZA200701789B (en) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072302L (no) | Modulatorer av hepatocyttvekstfaktoraktivator | |
| DK1877390T3 (da) | Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf | |
| DK1778236T3 (da) | Modificerede pyrimidin-glucocorticoid-receptor-modulatorer | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| DK1879573T3 (da) | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf | |
| DK1768490T3 (da) | Systemer og fremgangsmåder til ex-vivo-organpleje | |
| CR9869A (es) | Compuestos activos en ppar | |
| NO20091083L (no) | Organiske forbindelser | |
| NO20090046L (no) | Preparater og fremgangsmater for modulering av vaskulaer utvikling | |
| IL244803B (en) | Human anti-beta antibodies and their use | |
| TW200613731A (en) | Flow modulation devices | |
| CO6351784A2 (es) | Formas cristalinas de dimetoxi-docetaxel y sus procedimeintos de preparacion | |
| DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
| DK1910395T3 (da) | Sammensætninger og fremgangsmåder til modulation af SMN2-splejsning | |
| TW200640924A (en) | VEGF-R2 inhibitors and methods | |
| NO20071127L (no) | Triazoloftalaziner | |
| NO20082182L (no) | Sammensetninger og fremgangsmater for modulering av hemostase | |
| DK1682530T3 (da) | Pyrrolsubstituerede indoler som inhibitorer af PAI-1 | |
| DK1761497T3 (da) | Azadecalinglucocorticoidreceptormodulatorer | |
| EP1633311A4 (en) | COMPOSITIONS AND METHOD FOR MODULATING S-NITROSOGLUTATHION REDUCTASE | |
| NO20075140L (no) | Fremgangsmater og preparater for modulering av vaskulaer integritet | |
| EA200700702A1 (ru) | Аналоги локсапина и способы их применения | |
| TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
| EA200701293A1 (ru) | Терапевтическая композиция фактора роста кератиноцитов | |
| MX2012002013A (es) | Moduladores de activador del factor de crecimiento de hepatocitos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |